Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144293 | 1.00 | MGAM (0.42) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL1144297 | 1.00 | MGAM (0.42) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL5808284 | 0.83 | TSHR (0.41) | MTNR1AMTNR1BTSHRACACBALDH1A1 | |
| SCHEMBL16367683 | 0.82 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12164763 | 0.82 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8972302 | 0.82 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL22246440 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL1405629 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL13356642 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL17208359 | 0.80 | TSHR (0.39) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110683960-A | Synthesis method of (R) -3-aminobutanol | 台州达辰药业有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-9029571-B2 | Device and method for evaluating organic material for organic solar cell | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| CN-102985431-B | Method for producing optically active 1,2-bis(dialkylphosphino)benzene derivative | NIPPON CHEMICAL IND | 2014-12-03 | — | — | CN | disclosed |
| US-20140213800-A1 | DEVICE AND METHOD FOR EVALUATING ORGANIC MATERIAL FOR ORGANIC SOLAR CELL | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| CN-102985431-A | Method for producing optically active 1,2-bis(dialkylphosphino)benzene derivative | NIPPON CHEMICAL IND | 2013-03-20 | — | — | CN | disclosed |
| CN-101328134-B | Method for splitting 3-acetamido methyl butyrate antipode | BAOSHAN IRON & STEEL | 2011-07-06 | — | — | CN | disclosed |
| US-7893296-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| CN-101328134-A | Method for splitting 3-acetamido methyl butyrate antipode | BAOSHAN IRON & STEEL (CN) | 2008-12-24 | — | — | CN | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213800-A1 | DEVICE AND METHOD FOR EVALUATING ORGANIC MATERIAL FOR ORGANIC SOLAR CELL | HAO2, HAO1, DAO | MGAM 3934/4885GAA 3049/4885SI 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.